Albireo Pharma (ALBO) Files $400M Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Albireo Reports Q2 2022 Financial Results and Business Update
August 15, 2022 4:05 PM EDTBylvay®(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 millionAgreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fallGlobal Phase 3 ASSERT study in Alagille syndrome on track for topline data readout this fallGlobal Phase 3 BOLD study in biliary atresia on track for full enrollment in 2022Company to host a conference call and webcast today at 4:30 p.m. ET
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company... More
